Studies have shown that p53 knockdown or damage in colorectal cancer, large cell lung cancer, and breast epithelial cells increases sensitivity to PLK1 inhibitor-induced cytotoxicity (Guan et al., 2005; Degenhardt et al., 2010; Sur et al., 2009). Here, PLK1 is linked to colorectal cancer.